Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro C Barata

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
The Oncologist|September 27, 2025
Addressing quality-of-life challenges for patients with end-stage metastatic castrate-resistant prostate cancerAlbert Jang, Abby L Grier, Pedro C Barata
Cancer Management and Research|September 20, 2019
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamideAnita Gul, Jorge A Garcia, Pedro C Barata
Translational Andrology and Urology|March 11, 2026
Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for allViviane P Basilio de Souza, Pedro C Barata
Journal of Kidney Cancer and VHL|July 21, 2017
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF InhibitionPedro C Barata, Moshe C Ornstein, Jorge A Garcia
Clinical Genitourinary Cancer|March 31, 2026
Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate CancerPedro C Barata, Lauren Green, Christopher Kim, et al.
Cancers|May 30, 2020
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand TherapyWallace Jones, Kelly Griffiths, Pedro C Barata, et al.
Therapeutic Advances in Urology|May 5, 2021
Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinomaJason R Brown, Spencer Krane, Jorge Garcia, et al.
Cancers|November 25, 2020
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate CancerAlbert Jang, Oliver Sartor, Pedro C Barata, et al.
Expert Review of Anticancer Therapy|June 9, 2020
Non-metastatic castration-resistant prostate cancer: current status and future directionsRuby Gupta, Iris Y Sheng, Pedro C Barata, et al.
Current Treatment Options in Oncology|January 13, 2021
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell CarcinomaBryce R Christensen, Yasmin M Hajja, Vadim Koshkin, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
The Oncologist|September 27, 2025
Addressing quality-of-life challenges for patients with end-stage metastatic castrate-resistant prostate cancerAlbert Jang, Abby L Grier, Pedro C Barata
Cancer Management and Research|September 20, 2019
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamideAnita Gul, Jorge A Garcia, Pedro C Barata
Translational Andrology and Urology|March 11, 2026
Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for allViviane P Basilio de Souza, Pedro C Barata
Journal of Kidney Cancer and VHL|July 21, 2017
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF InhibitionPedro C Barata, Moshe C Ornstein, Jorge A Garcia
Clinical Genitourinary Cancer|March 31, 2026
Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate CancerPedro C Barata, Lauren Green, Christopher Kim, et al.
Cancers|May 30, 2020
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand TherapyWallace Jones, Kelly Griffiths, Pedro C Barata, et al.
Therapeutic Advances in Urology|May 5, 2021
Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinomaJason R Brown, Spencer Krane, Jorge Garcia, et al.
Cancers|November 25, 2020
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate CancerAlbert Jang, Oliver Sartor, Pedro C Barata, et al.
Expert Review of Anticancer Therapy|June 9, 2020
Non-metastatic castration-resistant prostate cancer: current status and future directionsRuby Gupta, Iris Y Sheng, Pedro C Barata, et al.
Current Treatment Options in Oncology|January 13, 2021
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell CarcinomaBryce R Christensen, Yasmin M Hajja, Vadim Koshkin, et al.
Pageof 13